Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 January 1997 | Volume 126 Issue 1 | Pages 32-35
Background: Women with polycystic ovaries have associated risk factors for coronary artery disease. It is unknown whether women with more extensive coronary artery disease are more likely to have polycystic ovaries.
Objective: To determine whether women who have more extensive coronary artery disease as seen on coronary angiography are more likely to have polycystic ovaries appearing on ultrasonography than are women with less severe coronary disease.
Design: Prevalence study of women who had had coronary angiography.
Setting: Women referred for coronary angiography for assessment of chest pain or valvular disease in Auckland, New Zealand, during a 2-year period.
Patients: 143 women 60 years of age or younger who had had coronary angiography. Women who had previously had bilateral oophorectomy were excluded.
Measurements: The extent of coronary artery disease assessed by quantitative angiography was compared with the presence or absence of polycystic ovaries. Pelvic ultrasonography was done without knowledge of the extent of coronary artery disease. Assessment of angiograms was blinded. Insulin resistance and gonadotropin, testosterone, and serum lipid levels were also measured.
Results: Polycystic ovaries were found in 42% of women and were associated with hirsutism; previous hysterectomy; higher free testosterone, triglyceride, and C-peptide levels; and lower high-density lipoprotein cholesterol levels. Women with polycystic ovaries had more extensive coronary artery disease than women with normal ovaries (number of segments with >50% stenosis, 1.7 [95% CI, 1.1 to 2.3] compared with 0.82 [CI, 0.54 to 1.1]; P < 0.01). On logistic regression analysis, the extent of coronary artery disease (P = 0.032) and family history of heart disease (P = 0.022) were predictors of the presence of polycystic ovaries.
Conclusions: In women having coronary angiography, those with more extensive coronary artery disease were more likely to have polycystic ovaries on ultrasonography than were those with less extensive disease. Visualization of polycystic ovaries by sonography was associated with distinct metabolic and endocrine abnormalities. Further study is required to evaluate whether surgery or hormone replacement therapy can modify the risk.
BRIEF COMMUNICATION
Association between Polycystic Ovaries and Extent of Coronary Artery Disease in Women Having Cardiac Catheterization
This article has been cited by other articles:
![]() |
R. Shroff, A. Kerchner, M. Maifeld, E. J. R. Van Beek, D. Jagasia, and A. Dokras Young Obese Women with Polycystic Ovary Syndrome Have Evidence of Early Coronary Atherosclerosis J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4609 - 4614. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Celik, I. Sahin, N. Celik, S. Hascalik, L. Keskin, H. Ozcan, A. Uckan, and F. Kosar Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study Hum. Reprod., November 1, 2007; 22(11): 2992 - 2998. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Vigorito, F. Giallauria, S. Palomba, T. Cascella, F. Manguso, R. Lucci, A. De Lorenzo, D. Tafuri, G. Lombardi, A. Colao, et al. Beneficial Effects of a Three-Month Structured Exercise Training Program on Cardiopulmonary Functional Capacity in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1379 - 1384. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Macut, S. Damjanovic, D. Panidis, N. Spanos, B. Glisic, M. Petakov, D. Rousso, A. Kourtis, J. Bjekic, and N. Milic Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS. Eur. J. Endocrinol., July 1, 2006; 155(1): 131 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Casquero, J. A. Berti, A. G. Salerno, E. J. B. Bighetti, P. M. Cazita, D. F. J. Ketelhuth, M. Gidlund, and H. C. F. Oliveira Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice J. Lipid Res., July 1, 2006; 47(7): 1526 - 1534. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Dursun, E. Demirtas, A. Bayrak, and H. Yarali Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum. Reprod., January 1, 2006; 21(1): 104 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kravariti, K. K. Naka, S. N. Kalantaridou, N. Kazakos, C. S. Katsouras, A. Makrigiannakis, E. A. Paraskevaidis, G. P. Chrousos, A. Tsatsoulis, and L. K. Michalis Predictors of Endothelial Dysfunction in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5088 - 5095. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A Christy, A. S Franks, and L B. Cross Spironolactone for Hirsutism in Polycystic Ovary Syndrome Ann. Pharmacother., September 1, 2005; 39(9): 1517 - 1521. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dokras, M. Bochner, E. Hollinrake, S. Markham, B. VanVoorhis, and D. H. Jagasia Screening Women With Polycystic Ovary Syndrome for Metabolic Syndrome Obstet. Gynecol., July 1, 2005; 106(1): 131 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Ford and S. Liu Invited Commentary: Acne in Adolescence--Protecting the Heart but Damaging the Prostate Later in Life? Am. J. Epidemiol., June 15, 2005; 161(12): 1102 - 1106. [Full Text] [PDF] |
||||
![]() |
E Diamanti-Kandarakis, K Alexandraki, A Protogerou, C Piperi, C Papamichael, A Aessopos, J Lekakis, and M Mavrikakis Metformin administration improves endothelial function in women with polycystic ovary syndrome Eur. J. Endocrinol., May 1, 2005; 152(5): 749 - 756. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vryonidou, A. Papatheodorou, A. Tavridou, T. Terzi, V. Loi, I.-A. Vatalas, N. Batakis, C. Phenekos, and A. Dionyssiou-Asteriou Association of Hyperandrogenemic and Metabolic Phenotype with Carotid Intima-Media Thickness in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2740 - 2746. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Dubey, B. Imthurn, M. Barton, and E. K. Jackson Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen Cardiovasc Res, May 1, 2005; 66(2): 295 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sutton-Tyrrell, R. P. Wildman, K. A. Matthews, C. Chae, B. L. Lasley, S. Brockwell, R. C. Pasternak, D. Lloyd-Jones, M. F. Sowers, J. I. Torrens, et al. Sex Hormone-Binding Globulin and the Free Androgen Index Are Related to Cardiovascular Risk Factors in Multiethnic Premenopausal and Perimenopausal Women Enrolled in the Study of Women Across the Nation (SWAN) Circulation, March 15, 2005; 111(10): 1242 - 1249. [Abstract] [Full Text] [PDF] |
||||
![]() |
A S T Bickerton, N Clark, D Meeking, K M Shaw, M Crook, P Lumb, C Turner, and M H Cummings Cardiovascular risk in women with polycystic ovarian syndrome (PCOS) J. Clin. Pathol., February 1, 2005; 58(2): 151 - 154. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. O. Talbott, J. V. Zborowski, J. R. Rager, M. Y. Boudreaux, D. A. Edmundowicz, and D. S. Guzick Evidence for an Association between Metabolic Cardiovascular Syndrome and Coronary and Aortic Calcification among Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5454 - 5461. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Orio Jr., S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, and A. Colao The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3696 - 3701. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Boulman, Y. Levy, R. Leiba, S. Shachar, R. Linn, O. Zinder, and Z. Blumenfeld Increased C-Reactive Protein Levels in the Polycystic Ovary Syndrome: A Marker of Cardiovascular Disease J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2160 - 2165. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Norman, M. Noakes, R. Wu, M. J. Davies, L. Moran, and J. X. Wang Improving reproductive performance in overweight/obese women with effective weight management Hum. Reprod. Update, May 1, 2004; 10(3): 267 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Bloomgarden Definitions of the Insulin Resistance Syndrome: The 1st World Congress on the Insulin Resistance Syndrome Diabetes Care, March 1, 2004; 27(3): 824 - 830. [Full Text] [PDF] |
||||
![]() |
M. T. Sheehan Polycystic Ovarian Syndrome: Diagnosis and Management Clin. Med. Res., February 1, 2004; 2(1): 13 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Rexrode, J. E. Manson, I-M. Lee, P. M Ridker, P. M. Sluss, N. R. Cook, and J. E. Buring Sex Hormone Levels and Risk of Cardiovascular Events in Postmenopausal Women Circulation, October 7, 2003; 108(14): 1688 - 1693. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Sharpless Polycystic Ovary Syndrome and the Metabolic Syndrome Clin. Diabetes, October 1, 2003; 21(4): 154 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Legro Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association? Endocr. Rev., June 1, 2003; 24(3): 302 - 312. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Y. Liu, A. K. Death, and D. J. Handelsman Androgens and Cardiovascular Disease Endocr. Rev., June 1, 2003; 24(3): 313 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Christian, D. A. Dumesic, T. Behrenbeck, A. L. Oberg, P. F. Sheedy II, and L. A. Fitzpatrick Prevalence and Predictors of Coronary Artery Calcification in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2562 - 2568. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932. [Full Text] [PDF] |
||||
![]() |
D. Dereli, G. Ozgen, F. Buyukkececi, E. Guney, and C. Yilmaz Platelet Dysfunction in Lean Women with Polycystic Ovary Syndrome and Association with Insulin Sensitivity J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2263 - 2268. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. W. Wu and A. von Eckardstein Androgens and Coronary Artery Disease Endocr. Rev., April 1, 2003; 24(2): 183 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Baltatu, C. Cayla, R. Iliescu, D. Andreev, and M. Bader Abolition of End-Organ Damage by Antiandrogen Treatment in Female Hypertensive Transgenic Rats Hypertension, March 1, 2003; 41(3): 830 - 833. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Nestler Should patients with polycystic ovarian syndrome be treated with metformin?: An enthusiastic endorsement Hum. Reprod., August 1, 2002; 17(8): 1950 - 1953. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Lakhani, A. M. Seifalian, and P. Hardiman Impaired Carotid Viscoelastic Properties in Women With Polycystic Ovaries Circulation, July 2, 2002; 106(1): 81 - 85. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. G. Kelly, H. Lyall, J. R. Petrie, G. W. Gould, J. M. C. Connell, A. Rumley, G. D. O. Lowe, and N. Sattar A Specific Elevation in Tissue Plasminogen Activator Antigen in Women with Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3287 - 3290. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Solomon, F. B. Hu, A. Dunaif, J. E. Rich-Edwards, M. J. Stampfer, W. C. Willett, F. E. Speizer, and J. E. Manson Menstrual Cycle Irregularity and Risk for Future Cardiovascular Disease J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2013 - 2017. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Sader and D. S. Celermajer Endothelial function, vascular reactivity and gender differences in the cardiovascular system Cardiovasc Res, February 15, 2002; 53(3): 597 - 604. [Full Text] [PDF] |
||||
![]() |
C. J. G. Kelly, A. Speirs, G. W. Gould, J. R. Petrie, H. Lyall, and J. M. C. Connell Altered Vascular Function in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 742 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Diamanti-Kandarakis, G. Spina, C. Kouli, and I. Migdalis Increased Endothelin-1 Levels in Women with Polycystic Ovary Syndrome and the Beneficial Effect of Metformin Therapy J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4666 - 4673. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. J. Kelly, H. Lyall, J. R. Petrie, G. W. Gould, J. M. C. Connell, and N. Sattar Low Grade Chronic Inflammation in Women with Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2453 - 2455. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Paradisi, H. O. Steinberg, A. Hempfling, J. Cronin, G. Hook, M. K. Shepard, and A. D. Baron Polycystic Ovary Syndrome Is Associated With Endothelial Dysfunction Circulation, March 13, 2001; 103(10): 1410 - 1415. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Mather, E. G. Norman, J. C. Prior, and T. G. Elliott Preserved Forearm Endothelial Responses with Acute Exposure to Progesterone: A Randomized Cross-Over Trial of 17-{beta} Estradiol, Progesterone, and 17-{beta} Estradiol with Progesterone in Healthy Menopausal Women J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4644 - 4649. [Abstract] [Full Text] |
||||
![]() |
R. A. Lobo and E. Carmina The Importance of Diagnosing the Polycystic Ovary Syndrome Ann Intern Med, June 20, 2000; 132(12): 989 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Mather, S. Verma, B. Corenblum, and T. J. Anderson Normal Endothelial Function Despite Insulin Resistance in Healthy Women with the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1851 - 1856. [Abstract] [Full Text] |
||||
![]() |
C. S. Hayward, R. P. Kelly, and P. Collins The roles of gender, the menopause and hormone replacement on cardiovascular function Cardiovasc Res, April 1, 2000; 46(1): 28 - 49. [Full Text] [PDF] |
||||
![]() |
P. L. Chang, S. R. Lindheim, C. Lowre, M. Ferin, F. Gonzalez, L. Berglund, E. Carmina, M. V. Sauer, and R. A. Lobo Normal Ovulatory Women with Polycystic Ovaries Have Hyperandrogenic Pituitary-Ovarian Responses To Gonadotropin-Releasing Hormone-Agonist Testing J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 995 - 1000. [Abstract] [Full Text] |
||||
![]() |
S. Lemieux, G. F. Lewis, A. Ben-Chetrit, G. Steiner, and E. M. Greenblatt Correction of Hyperandrogenemia by Laparoscopic Ovarian Cautery in Women with Polycystic Ovarian Syndrome Is Not Accompanied by Improved Insulin Sensitivity or Lipid-Lipoprotein Levels J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4278 - 4282. [Abstract] [Full Text] |
||||
![]() |
E. Carmina and R. A. Lobo Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1897 - 1899. [Full Text] |
||||
![]() |
R. J. McCredie, J. A. McCrohon, L. Turner, K. A. Griffiths, D. J. Handelsman, and D. S. Celermajer Vascular reactivity is impaired in genetic females taking high-dose androgens J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1331 - 1335. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. E C Hopkinson, N. Sattar, R. Fleming, and I. A Greer Fortnightly Review: Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology BMJ, August 1, 1998; 317(7154): 329 - 332. [Full Text] |
||||
![]() |
A. H. Slyper Childhood Obesity, Adipose Tissue Distribution, and the Pediatric Practitioner Pediatrics, July 1, 1998; 102(1): 4e - 4. [Abstract] [Full Text] |
||||
![]() |
A. Dunaif Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis Endocr. Rev., December 1, 1997; 18(6): 774 - 800. [Abstract] [Full Text] |
||||
![]() |
D. A. Ehrmann, D. J. Schneider, B. E. Sobel, M. K. Cavaghan, J. Imperial, R. L. Rosenfield, and K. S. Polonsky Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2108 - 2116. [Abstract] [Full Text] [PDF] |
||||
![]() |
Polycystic Ovaries: A Risk Factor for Coronary Artery Disease ? Journal Watch Cardiology, February 11, 1997; 1997(211): 6 - 6. [Full Text] |
||||